ArticleZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2025
[Chinese expert consensus on quality control, result analysis, and reporting of anti-HLA antibody testing in allogeneic hematopoietic stem cell transplantation (2025)].
Article in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- [Chinese expert consensus on the clinical interpretation of donor-specific anti-HLA antibody test results in HLA-mismatched hematopoietic stem cell transplantation (2025)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibodies against human leukocyte antigens (HLA) are closely related to engraftment, hematopoietic reconstitution, graft-versus-host disease, and are crucial for guiding treatment strategies and prognostic assessment in allogeneic hematopoietic stem cell transplantation (allo-HSCT) . The anti-HLA antibody detection and result analysis are not only affected by the inherent limitations and sensitivity of the testing methods, but also depend on the performance validation of key procedures, comprehensive quality, and standardized data analysis, which demand higher standards for result interpretation and reporting. To address these issues, the Experimental Diagnostics Group, Chinese Society of Hematology, Chinese Medical Association has developed this expert consensus, aiming to make the anti-HLA antibody detection play a more important role in the clinical diagnosis and treatment of allo-HSCT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.